Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMUNOR oral immunomodulatory therapy in moderate COVID-19
2020-002497-27Phase 4Completed
- Sponsor
- Thomayer University Hospital
- Start
- Oct 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Imunor oral therapy with Control (standard of care only) (2 arms). Primary endpoint: Change in symptom score within 2 weeks of starting Imunor. Started Oct 2020; status: completed.
02
Drugs
Imunor
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002497-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002497-27.